301 related articles for article (PubMed ID: 23933525)
1. Adjuvant formulation structure and composition are critical for the development of an effective vaccine against tuberculosis.
Orr MT; Fox CB; Baldwin SL; Sivananthan SJ; Lucas E; Lin S; Phan T; Moon JJ; Vedvick TS; Reed SG; Coler RN
J Control Release; 2013 Nov; 172(1):190-200. PubMed ID: 23933525
[TBL] [Abstract][Full Text] [Related]
2. Prophylactic efficacy against Mycobacterium tuberculosis using ID93 and lipid-based adjuvant formulations in the mouse model.
Baldwin SL; Reese VA; Larsen SE; Beebe E; Guderian J; Orr MT; Fox CB; Reed SG; Coler RN
PLoS One; 2021; 16(3):e0247990. PubMed ID: 33705411
[TBL] [Abstract][Full Text] [Related]
3. The importance of adjuvant formulation in the development of a tuberculosis vaccine.
Baldwin SL; Bertholet S; Reese VA; Ching LK; Reed SG; Coler RN
J Immunol; 2012 Mar; 188(5):2189-97. PubMed ID: 22291184
[TBL] [Abstract][Full Text] [Related]
4. A dual TLR agonist adjuvant enhances the immunogenicity and protective efficacy of the tuberculosis vaccine antigen ID93.
Orr MT; Beebe EA; Hudson TE; Moon JJ; Fox CB; Reed SG; Coler RN
PLoS One; 2014; 9(1):e83884. PubMed ID: 24404140
[TBL] [Abstract][Full Text] [Related]
5. Long-term protective efficacy with a BCG-prime ID93/GLA-SE boost regimen against the hyper-virulent Mycobacterium tuberculosis strain K in a mouse model.
Kwon KW; Lee A; Larsen SE; Baldwin SL; Coler RN; Reed SG; Cho SN; Ha SJ; Shin SJ
Sci Rep; 2019 Oct; 9(1):15560. PubMed ID: 31664157
[TBL] [Abstract][Full Text] [Related]
6. MyD88 and TRIF synergistic interaction is required for TH1-cell polarization with a synthetic TLR4 agonist adjuvant.
Orr MT; Duthie MS; Windish HP; Lucas EA; Guderian JA; Hudson TE; Shaverdian N; O'Donnell J; Desbien AL; Reed SG; Coler RN
Eur J Immunol; 2013 Sep; 43(9):2398-408. PubMed ID: 23716300
[TBL] [Abstract][Full Text] [Related]
7. Protection against Mycobacterium leprae infection by the ID83/GLA-SE and ID93/GLA-SE vaccines developed for tuberculosis.
Duthie MS; Coler RN; Laurance JD; Sampaio LH; Oliveira RM; Sousa AL; Stefani MM; Maeda Y; Matsuoka M; Makino M; Reed SG
Infect Immun; 2014 Sep; 82(9):3979-85. PubMed ID: 25024362
[TBL] [Abstract][Full Text] [Related]
8. Mucosal delivery switches the response to an adjuvanted tuberculosis vaccine from systemic TH1 to tissue-resident TH17 responses without impacting the protective efficacy.
Orr MT; Beebe EA; Hudson TE; Argilla D; Huang PW; Reese VA; Fox CB; Reed SG; Coler RN
Vaccine; 2015 Nov; 33(48):6570-8. PubMed ID: 26541135
[TBL] [Abstract][Full Text] [Related]
9. Pulmonary immunity and durable protection induced by the ID93/GLA-SE vaccine candidate against the hyper-virulent Korean Beijing Mycobacterium tuberculosis strain K.
Cha SB; Kim WS; Kim JS; Kim H; Kwon KW; Han SJ; Cho SN; Coler RN; Reed SG; Shin SJ
Vaccine; 2016 Apr; 34(19):2179-87. PubMed ID: 27005808
[TBL] [Abstract][Full Text] [Related]
10. Protection against tuberculosis with homologous or heterologous protein/vector vaccine approaches is not dependent on CD8+ T cells.
Baldwin SL; Ching LK; Pine SO; Moutaftsi M; Lucas E; Vallur A; Orr MT; Bertholet S; Reed SG; Coler RN
J Immunol; 2013 Sep; 191(5):2514-2525. PubMed ID: 23904160
[TBL] [Abstract][Full Text] [Related]
11. Combinational PRR Agonists in Liposomal Adjuvant Enhances Immunogenicity and Protective Efficacy in a Tuberculosis Subunit Vaccine.
Hao L; Wu Y; Zhang Y; Zhou Z; Lei Q; Ullah N; Banga Ndzouboukou JL; Lin X; Fan X
Front Immunol; 2020; 11():575504. PubMed ID: 33117374
[TBL] [Abstract][Full Text] [Related]
12. Potentiation of Th1-Type Immune Responses to
Ko A; Wui SR; Ryu JI; Lee YJ; Hien DTT; Rhee I; Shin SJ; Park SA; Kim KS; Cho YJ; Lee NG
J Microbiol Biotechnol; 2018 Jan; 28(1):136-144. PubMed ID: 29081214
[TBL] [Abstract][Full Text] [Related]
13. Protection against Mycobacterium tuberculosis infection offered by a new multistage subunit vaccine correlates with increased number of IFN-γ+ IL-2+ CD4+ and IFN-γ+ CD8+ T cells.
Wang X; Zhang J; Liang J; Zhang Y; Teng X; Yuan X; Fan X
PLoS One; 2015; 10(3):e0122560. PubMed ID: 25822536
[TBL] [Abstract][Full Text] [Related]
14. Correlates of GLA family adjuvants' activities.
Reed SG; Carter D; Casper C; Duthie MS; Fox CB
Semin Immunol; 2018 Oct; 39():22-29. PubMed ID: 30366662
[TBL] [Abstract][Full Text] [Related]
15. Cell wall skeleton of Mycobacterium bovis BCG enhances the vaccine potential of antigen 85B against tuberculosis by inducing Th1 and Th17 responses.
Back YW; Choi S; Choi HG; Shin KW; Son YJ; Paik TH; Kim HJ
PLoS One; 2019; 14(3):e0213536. PubMed ID: 30849108
[TBL] [Abstract][Full Text] [Related]
16. A comparison of antigen-specific T cell responses induced by six novel tuberculosis vaccine candidates.
Rodo MJ; Rozot V; Nemes E; Dintwe O; Hatherill M; Little F; Scriba TJ
PLoS Pathog; 2019 Mar; 15(3):e1007643. PubMed ID: 30830940
[TBL] [Abstract][Full Text] [Related]
17. A novel liposome adjuvant DPC mediates Mycobacterium tuberculosis subunit vaccine well to induce cell-mediated immunity and high protective efficacy in mice.
Liu X; Da Z; Wang Y; Niu H; Li R; Yu H; He S; Guo M; Wang Y; Luo Y; Ma X; Zhu B
Vaccine; 2016 Mar; 34(11):1370-8. PubMed ID: 26845736
[TBL] [Abstract][Full Text] [Related]
18. Development of a thermostable nanoemulsion adjuvanted vaccine against tuberculosis using a design-of-experiments approach.
Kramer RM; Archer MC; Orr MT; Dubois Cauwelaert N; Beebe EA; Huang PD; Dowling QM; Schwartz AM; Fedor DM; Vedvick TS; Fox CB
Int J Nanomedicine; 2018; 13():3689-3711. PubMed ID: 29983563
[TBL] [Abstract][Full Text] [Related]
19. Protection and Long-Lived Immunity Induced by the ID93/GLA-SE Vaccine Candidate against a Clinical Mycobacterium tuberculosis Isolate.
Baldwin SL; Reese VA; Huang PW; Beebe EA; Podell BK; Reed SG; Coler RN
Clin Vaccine Immunol; 2016 Feb; 23(2):137-47. PubMed ID: 26656121
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and protective efficacy of DMT liposome-adjuvanted tuberculosis subunit CTT3H vaccine.
Teng X; Tian M; Li J; Tan S; Yuan X; Yu Q; Jing Y; Zhang Z; Yue T; Zhou L; Fan X
Hum Vaccin Immunother; 2015; 11(6):1456-64. PubMed ID: 25905680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
